These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
448 related articles for article (PubMed ID: 33894221)
1. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways. Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221 [TBL] [Abstract][Full Text] [Related]
2. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells. Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520 [TBL] [Abstract][Full Text] [Related]
3. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2. Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477 [TBL] [Abstract][Full Text] [Related]
4. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT. Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858 [TBL] [Abstract][Full Text] [Related]
5. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells. Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587 [TBL] [Abstract][Full Text] [Related]
6. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer. Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611 [TBL] [Abstract][Full Text] [Related]
7. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma. Lu GS; Li M; Xu CX; Wang D Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076 [TBL] [Abstract][Full Text] [Related]
8. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201 [TBL] [Abstract][Full Text] [Related]
9. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074 [TBL] [Abstract][Full Text] [Related]
10. IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation. Ikink GJ; Boer M; Bakker ER; Hilkens J Nat Commun; 2016 Nov; 7():13567. PubMed ID: 27876799 [TBL] [Abstract][Full Text] [Related]
11. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177 [TBL] [Abstract][Full Text] [Related]
12. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway. Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070 [TBL] [Abstract][Full Text] [Related]
13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
14. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells. Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597 [TBL] [Abstract][Full Text] [Related]
15. RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer. Kaneto N; Yokoyama S; Hayakawa Y; Kato S; Sakurai H; Saiki I Cancer Sci; 2014 Jul; 105(7):788-94. PubMed ID: 24750242 [TBL] [Abstract][Full Text] [Related]
16. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Li F; Zhu T; Cao B; Wang J; Liang L Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888 [TBL] [Abstract][Full Text] [Related]
17. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway. Zheng R; Jiang H; Li J; Liu X; Xu H Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061 [TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066 [TBL] [Abstract][Full Text] [Related]
19. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells. Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646 [TBL] [Abstract][Full Text] [Related]
20. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice. Chung CT; Yeh KC; Lee CH; Chen YY; Ho PJ; Chang KY; Chen CH; Lai YK; Chen CT Pharmacol Res; 2020 Nov; 161():105183. PubMed ID: 32896579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]